Results Published from PCCTC Study of Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy

Sep 13

Written By Kristofer Prepelica, PhD

Kristofer Prepelica, PhD

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

6th Annual NYC Prostate Cancer Summit to Feature PCCTC Investigators